Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture

BioRxiv : the Preprint Server for Biology
Kenneth H RisnerAarthi Narayanan


In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A screen of 19 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The screen identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that were able to inhibit SARS-CoV-2 infection. Confocal microscopy with over expressed S protein demonstrated that Maraviroc reduced the extent of S-protein mediated cell fusion as observed by fewer multinucleate cells in drug-treated cells. Mathematical modeling of drug-dependent viral multiplication dynamics revealed that prolonged drug treatment will exert an exponential decrease in viral load in a multicellular/tissue environment. Taken together, the data demonstrate that Maraviroc, Fingolimod, Atorvastatin and Nitazoxanide inhibit SARS-CoV-2 in cell culture. Maraviroc, FTY720, Nitazoxanide and Atorvastatin inhibit SARS-CoV-2 multiplication in cell culture.Maraviroc does not interfere with the interaction between SARS-CoV-2 spike protein a...Continue Reading


Nov 5, 2020·Clinical Medicine : Journal of the Royal College of Physicians of London·Deborah R Tasat, Juan S Yakisich
Jun 12, 2021·International Immunopharmacology·Elías Cuesta-LlavonaEliecer Coto

Methods Mentioned

confocal microscopy

Clinical Trials Mentioned


Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.